文献速递肿瘤 PET/CT放射性药物与辐射防护

Fc工程化单克隆抗体减少脱靶肝脏摄取

Fc-engineered monoclonal antibodies to reduce off-target liver uptake.
PubMed 文献 · EJNMMI Res · 2023-09-11

本研究在小鼠移植瘤模型中比较了野生型Fc与LALAPG三重突变Fc(阻止与FcγR结合)的89Zr标记重组人IgG1抗体的生物分布。结果显示,突变Fc抗体的肝脏积聚强烈减少,肿瘤特异性靶向增加。作者认为,与FcγR结合减少的抗体显示更低的肝脏积聚和更好的肿瘤/肝脏比值,这些发现需在改进基于抗体的诊疗方法时加以考虑。

要点

  • 突变Fc(LALAPG三重突变)抗体较野生型Fc抗体肝脏积聚强烈减少。
  • 突变Fc抗体较野生型Fc抗体肿瘤特异性靶向增加。
  • 与FcγR结合减少的抗体显示更低肝脏积聚和更好肿瘤/肝脏比值。

核心结论

  • 与FcγR结合减少的抗体显示更低的肝脏积聚和更好的肿瘤/肝脏比值。
  • 这些发现需在改进基于抗体的诊疗方法时加以考虑。

研究设计与样本

  • 研究比较了野生型Fc与LALAPG三重突变Fc(阻止与FcγR结合)的89Zr标记重组人IgG1抗体(针对不同靶点)。
  • 抗体注射入携带不同肿瘤细胞系或永生化人成肌细胞移植瘤的小鼠后,通过PET-CT和常规生物分布分析评估抗体生物分布。

主要发现

  • 与野生型Fc相比,突变Fc抗体的肝脏积聚强烈减少。
  • 与野生型Fc相比,突变Fc抗体的肿瘤特异性靶向增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiolabeled-antibodies usually display non-specific liver accumulation that may impair image analysis and antibody biodistribution. Here, we investigated whether Fc silencing influenced antibody biodistribution. We compared recombinant 89Zr-labeled antibodies (human IgG1 against different targets) with wild-type Fc and with mutated Fc (LALAPG triple mutation to prevent binding to Fc gamma receptors; FcγR). After antibody injection in mice harboring xenografts of different tumor cell lines or of immortalized human myoblasts, we analyzed antibody biodistribution by PET-CT and conventional biodistribution analysis. RESULTS: Accumulation in liver was strongly reduced and tumor-specific targeting was increased for the antibodies with mutated Fc compared with wild-type Fc. CONCLUSION: Antibodies with reduced binding to FcγR display lower liver accumulation and better tumor-to-liver ratios. These findings need to be taken into account to improve antibody-based theragnostic approaches.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mangeat T, Gracia M, Pichard A, et al. Fc-engineered monoclonal antibodies to reduce off-target liver uptake. EJNMMI Res. 2023. PMID: 37697076. doi:10.1186/s13550-023-01030-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。